Meeting
2013 ASCO Annual Meeting
A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes.
Authors
Ignace Vergote
UZ Leuven, Leuven, Belgium
Ignace Vergote , Michael Teneriello , Matthew A. Powell , David S. Miller , Agustin A. Garcia , Olga N. Mikheeva , Tamas Pinter , Mariusz Bidzinski , Cristina Ligia Cebotaru , Jean Fan , Min Ren , Nicole Meneses , Yasuhiro Funahashi , Tadashi Kadowaki , James P. O'Brien , Richard T. Penson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT01111461
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5520)
DOI
10.1200/jco.2013.31.15_suppl.5520
Abstract #
5520
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Analysis of plasma biomarker and tumor genetic alterations from a phase II trial of lenvatinib in patients with advanced endometrial cancer.
First Author: Yasuhiro Funahashi
Poster
2023 ASCO Annual Meeting
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
First Author: Elizabeth Katherine Lee
Poster
2020 ASCO Virtual Scientific Program
A Big Ten Cancer Research Consortium phase II trial of pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer.
First Author: Mario Javier Pineda
Poster
2017 ASCO Annual Meeting
Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia.
First Author: Neesha C. Dhani